Shun-Chiao Chang

Dr. Shun-Chiao Chang

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in The American Journal of Clinical Nutrition
Verified
Journal Article
Open access
PDF file
SCShun-Chiao Chang
Shun-Chiao Chang
ACAedin Cassidy
Aedin Cassidy
WWWalter Willett
Walter Willett
EREric B Rimm
Eric B Rimm
EOEilis J O’reilly
Eilis J O’reilly
OOOlivia I Okereke
Olivia I Okereke
Background: The impact of dietary flavonoid intakes on risk of depression is unclear.Objective: We prospectively examined associations between estimat

22 December 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
GCGenaro Castillon
Genaro Castillon
SCShun-Chiao Chang
Shun-Chiao Chang
YMYola Moride
Yola Moride
Incidence and prevalence estimates for Gaucher disease (GD) are scarce for this rare disease and can be variable within the same region. This review provides a qualitative synthesis of global GD incidence and prevalence estimates, GD1–3 type-specific and overall, published in the last 10 years. A targeted literature search was conducted across multiple databases from January 2011 to September 2020, including web-based sources and congress proceedings to May 2021. Searches yielded 490 publications, with 31 analyzed: 20 cohort studies (15 prospective, 5 retrospective), 6 cross-sectional studies, 5 online reports (most from Europe (n = 11) or North America (n = 11); one multiregional). Across all GD types, incidence estimates ranged 0.45–25.0/100,000 live births (16 studies), lowest for Asia-Pacific. Incidence of GD1: 0.45–22.9/100,000 live births (Europe and North America) and GD3: 1.36/100,000 live births (Asia-Pacific only). GD type-specific prevalence estimates per 100,000 population were GD1: 0.26–0.63; GD2 and GD3: 0.02–0.08 (Europe only); estimates for GD type unspecified or overall ranged 0.11–139.0/100,000 inhabitants (17 studies), highest for North America. Generalizability was assessed as “adequate”or “intermediate” for all regions with data. GD incidence and prevalence estimates for the last 10 years varied considerably between regions and were poorly documented outside Europe and North America. Data for GD2 and GD3 were limited.

1 August 2018 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
Céline VetterCéline Vetter
Céline Vetter
SCShun-Chiao Chang
Shun-Chiao Chang
EDElizabeth E. Devore
Elizabeth E. Devore
FRFlorian Rohrer
Florian Rohrer
OOOlivia I. Okereke
Olivia I. Okereke
Eva SchernhammerEva Schernhammer
Eva Schernhammer

3 January 2020 in EPMA Journal
Verified
Journal Article
Closed access
PDF file
JBJeffrey S. Berger
Jeffrey S. Berger
LHLloyd Haskell
Lloyd Haskell
WTWindsor Ting
Windsor Ting
FLFedor Lurie
Fedor Lurie
SCShun-Chiao Chang
Shun-Chiao Chang
VAVeronica Alas
Veronica Alas

1 September 2018 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
EDElizabeth E. Devore
Elizabeth E. Devore
SCShun-Chiao Chang
Shun-Chiao Chang
OOOlivia I. Okereke
Olivia I. Okereke
DMDouglas G. McMahon
Douglas G. McMahon
ESEva S. Schernhammer
Eva S. Schernhammer

21 February 2024 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
SCShun-Chiao Chang
Shun-Chiao Chang
ABAurore Bergamasco
Aurore Bergamasco
MBMélanie Bonnin
Mélanie Bonnin
TBTeigna Arredondo Bisonó
Teigna Arredondo Bisonó
YMYola Moride
Yola Moride
Background: Metachromatic leukodystrophy (MLD) is an autosomal recessive lysosomal storage disease caused by deficiency in arylsulfatase A (ASA) activity arising primarily from ASA gene (ARSA) variants. Late-infantile, juvenile and adult clinical subtypes are defined by symptom onset at ≤ 2.5, > 2.5 to < 16 and ≥ 16 years, respectively. Epidemiological data were sought to address knowledge gaps and to inform decisions regarding the clinical development of an investigational drug. Methods: To synthesize all available estimates of MLD incidence and birth prevalence worldwide and in selected countries, Ovid MEDLINE and Embase were searched systematically (March 11, 2022) using a population, intervention, comparator, outcome, time and setting framework, complemented by pragmatic searching to reduce publication bias. Where possible, results were stratified by clinical subtype. Data were extracted from non-interventional studies (clinical trials, non-clinical studies and case reports were excluded; reviews were used for snowballing only). Results: Of the 31 studies included, 14 reported birth prevalence (13 countries in Asia–Pacific, Europe, the Middle East, North America and South America), one reported prevalence and none reported incidence. Birth prevalence per 100,000 live births ranged from 0.16 (Japan) to 1.85 (Portugal). In the three European studies with estimates stratified by clinical subtypes, birth prevalence was highest for late-infantile cases (0.31–1.12 per 100,000 live births). The distribution of clinical subtypes reported in cases diagnosed over various time periods in 17 studies varied substantially, but late-infantile and juvenile MLD accounted for at least two-thirds of cases in most studies. Conclusions: This review provides a foundation for further analysis of the regional epidemiology of MLD. Data gaps indicate the need for better global coverage, increased use of epidemiological measures (e.g. prevalence estimates) and more stratification of outcomes by clinical and genetic disease subtype.